Evidence of Malignant Hyperthermia in Patients Administered Triggering Agents before Malignant Hyperthermia Susceptibility Identified: Missed Opportunities Prior to Diagnosis
暂无分享,去创建一个
N. Pollock | K. Stowell | T. Chan | R. Gillies | E. Langton | T. Bulger | N. Street
[1] S. Treves,et al. The Malignant Hyperthermia RYR1Y522S Mutation affects Calcium Homeostasis in Arterial Smooth Muscle Cells , 2016 .
[2] C. Müller,et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. , 2015, British journal of anaesthesia.
[3] P. Forget,et al. The Changing Face of Malignant Hyperthermia: Less Fulminant, More Insidious , 2015, Anaesthesia and intensive care.
[4] E. Lehman,et al. Malignant Hyperthermia Deaths Related to Inadequate Temperature Monitoring, 2007–2012: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States , 2014, Anesthesia and analgesia.
[5] C. Massey,et al. Malignant Hyperthermia in Canada: Characteristics of Index Anesthetics in 129 Malignant Hyperthermia Susceptible Probands , 2014, Anesthesia and analgesia.
[6] M. Roberts,et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis , 2013, Neuromuscular Disorders.
[7] Keisaku Sato,et al. Skeletal Muscle Ryanodine Receptor Mutations Associated with Malignant Hyperthermia Showed Enhanced Intensity and Sensitivity to Triggering Drugs when Expressed in Human Embryonic Kidney Cells , 2013, Anesthesiology.
[8] H. Hamada,et al. The severity of sevoflurane‐induced malignant hyperthermia , 2012, Acta anaesthesiologica Scandinavica.
[9] D. Baralle,et al. King–Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene , 2011, Neuromuscular Disorders.
[10] K. Stowell,et al. Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System. , 2008, Analytical biochemistry.
[11] W. Ummenhofer,et al. Re: masseter spasm after succinylcholine administration. , 2007, The Journal of emergency medicine.
[12] H. Rosenberg,et al. Orphanet Journal of Rare Diseases BioMed Central Review Malignant hyperthermia , 2007 .
[13] R. Krivosic-Horber,et al. Minor increase of endtidal CO2 during sevoflurane‐induced malignant hyperthermia , 2007, Paediatric anaesthesia.
[14] G. Islander,et al. Malignant hyperthermia and central core disease causative mutations in Swedish patients , 2007, Acta anaesthesiologica Scandinavica.
[15] P. Allen,et al. ENHANCED EXCITATION-COUPLED CALCIUM ENTRY IN MYOTUBES IS ASSOCIATED WITH EXPRESSION OF RYR 1 MH MUTATIONS , 2007 .
[16] A. Beggs,et al. X-Linked Myotubular and Centronuclear Myopathies , 2005, Journal of neuropathology and experimental neurology.
[17] V. Pietrini,et al. Adult onset multi/minicore myopathy associated with a mutation in the RYR1 gene , 2004, Journal of Neurology.
[18] V. Pietrini,et al. Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: evidence for a cluster of novel mutations in the C-terminal region. , 2002, Cell calcium.
[19] P. Hopkins. Malignant hyperthermia: advances in clinical management and diagnosis. , 2000, British journal of anaesthesia.
[20] F. Chung,et al. Succinylcholine‐associated postoperative myalgia , 2000, Anaesthesia.
[21] L. Skovgaard,et al. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test , 1997, Acta anaesthesiologica Scandinavica.
[22] P. Hopkins,et al. Serum and urinary myoglobin following an aborted malignant hyperthermia reaction , 1996, Anaesthesia.
[23] A. Localio,et al. A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.
[24] H. Rosenberg. Trismus is not trivial. , 1987, Anesthesiology.
[25] D. Moyes,et al. Unexpected hyperthermia manifesting during outpatient anesthesia. , 1986, Anesthesiology.
[26] M. Nahrwold,et al. Masseter Spasm and Malignant Hyperthermia Are Not the Same Thing , 1986 .
[27] A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. , 1984, British journal of anaesthesia.
[28] Britt Ba. Recent advances in malignant hyperthermia. , 1972 .
[29] B. Britt. Recent Advances in Malignant Hyperthermia , 1972, Anesthesia and analgesia.
[30] Newson Aj. Malignant hyperthermia: three case reports. , 1972 .
[31] B. Britt,et al. Malignant hyperthermia: A statistical review , 1970, Canadian Anaesthetists' Society journal.